Imunoterapia antitumoral em medicina veterinária
DOI:
https://doi.org/10.29327/multi.2021010Keywords:
anticorpos monoclonais, imunidade adaptativa, restauração imunológica, sistema imunitário, vacinas anticâncerAbstract
O tratamento para neoplasias é realizado principalmente por meio de cirurgias, quimioterapias e radioterapias. Entretanto, apesar do progresso geral na terapia contra o câncer, ainda são escassas as opções de tratamentos eficazes e até mesmo curativos para determinados grupos de pacientes oncológicos. A imunoterapia antitumoral se encaixa nesta lacuna, uma vez que consiste na manipulação do sistema imunológico do próprio paciente no intuito de identificar e destruir células neoplásicas. Nesse contexto, o presente estudo tem como objetivo revisar a literatura sobre a aplicação da imunoterapia antitumoral em medicina veterinária, seus efeitos colaterais e outros aspectos considerados pertinentes aos diferentes métodos. Além disso, a avaliação do padrão de resposta apresentada, bem como as células e componentes envolvidos foram consideradas. Para tanto, foram utilizados os sites de busca Medline, Scielo e Portal CAPES, utilizando as palavras-chaves tais como “imunoterapia antitumoral”, “anticorpos antineoplásicos” e “vacinas anticâncer”, para a seleção de artigos científicos dos últimos 10 anos. Apesar da imunoterapia agir de forma distinta de qualquer outro tipo de tratamento oncológico, sua indicação tem relação com as características do tumor e a fase do tratamento em que o paciente se encontra. A literatura abrange o estudo de diferentes estratégias de imunoterapia antitumoral com foco na aplicação em humanos; entretanto, a maioria dos testes e respostas avaliadas acontecem em diferentes espécies animais. Assim, fica claro o potencial de uso da imunoterapia antitumoral na medicina veterinária, no intuito de estimular respostas do sistema imune contra as células cancerígenas evitando a amplificação e propagação tumoral.
References
Berger M (2005) Estudo de fase I com vacina celular autóloga imunomodulada para tratamento de câncer de próstata localmente avançado ou metastático. Thesis, Universidade Federal do Rio Grande do Sul.
Bowers JS, Majchrzak K, Nelson MH, Aksoy BA, Wyatt MM, Smith, AS, Bailey SR, Neal LR, Hammerbacher JE, Paulos CM (2017) PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells. Frontiers in Immunology. doi: 10.3389/fimmu.2017.01221
Campos CB, Lavalle GE, Horta RS, Rodrigues AAM, Viana AAS, Carneiro RA (2011) Associação de cirurgia, quimioterapia e imunoterapia no tratamento de melanoma canino de cavidade oral – relato de dois casos. Veterinária e Zootecnia 18:80-85.
Caponero R (2018) Imunoterapia: métodos e aplicação no câncer. FEMAMA. Accessed on: March 13, 2021
Chang Y-H, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D (2013) A chimeric receptor with NKG2D specificity enhances Natural Killer cell activation and killing of tumor cells. Cancer Research 73(6).
Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA (2016) Anti-CCR4 monoclonal antibody enhances anti-tumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. doi: 10.1080/2162402X.2015.1090075
Cicchelero L, Denies S, Haers H, Vanderperren K, Stock E, Brantegem LV, Rooster H, Sanders NN (2016) Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer. Veterinary and Comparative Oncology. doi: 10.1111/vco.12255
Du X, Zhang B, Hu F, Xie C, Tian H, Gu Q, Gong H, Bai X, Zhang J (2020) The therapeutic effects of intratumoral injection of IL12IL2GMCSF fusion protein on canine tumors. bioRxiv. doi: 10.1101/2020.06.03.131904
Flesner BK, Wood GW, Gayheart-Walsten P, Sonderegger FL, Henry CJ, Tate DJ, Bechtel SM, Donnelly LL, Johnson GC, Kim DY, Wahaus, TA, Bryan JN, Reyes N (2020) Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin- 2 administration results in long-term survival for companion dogs with osteosarcoma. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.15852
Fossum TW (2014) Cirurgia de pequenos animais. Rio de Janeiro.
Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L (2013) Safety and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chemotherapy for the Therapy of Canine B-Cell Lymphoma. Human Gene Therapy. doi: 10.1089/hum.2013.112
Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, Szalay AA (2013) Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered. doi: 10.4161/bioe.22462
Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M (2011) CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis. PLoS One. doi: 10.1371/journal.pone.0020702
Impellizeri JA, Gavazza A, Greissworth E, Crispo A, Montella M, Ciliberto G, Lubas G, Aurisicchio L (2018) Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma. Journal of Translational Medicine. doi: 10.1186/s12967-018-1738-6
João CF (2012) Imunoterapia com a vacina heteróloga de DNAHSP65+PROTEÍNA-HSP65 de Mycobacterium leprae em tumores mamários de cadelas. Thesis, Universidade Estadual Paulista.
Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R (2009) Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncology. doi: 10.2217/FON.09.6
Kos S, Lopes A, Preat V, Cemazar M, Tratar UL, Ucakar B, Vanvarenberg K, Sersa G, Vandermeulen G (2019) Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. PLoS One. doi: 10.1371/journal.pone.0217762
Lee KM, An JH, Yang SJ, Park SM, Lee JH, Chae HK, Song WJ, Youn HY (2021) Influence of canine macrophage-derived extracellular vesicles on apoptosis in canine melanoma and osteosarcoma cell lines. Anticancer Research. doi: https://doi.org/10.21873/anticanres.14823
London CA, Gardner AH, Rippy S, Post G, Perle KL, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R (2017) KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-16-2152
Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, Kato Y, Yamamoto K, Uemura H, Suzuki Y, Murata S, Ohashi K (2017) A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports. doi: 10.1038/s41598-017-09444-2
Martins JLP (2018) Avaliação da utilização de imunoterapia com APAVAC® em cães e gatos com cancro – estudo retrospectivo de 20 casos. Dissertação, Universidade de Lisboa.
Mata M, Vera J, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S (2014) Towards immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. Journal of Immunotherapy. doi:10.1097/CJI.0000000000000052
Matoso LML, Rosário SSD, Matoso MBL (2015) As estratégias de cuidados para o alívio dos efeitos colaterais da quimioterapia em mulheres. Saúde (Santa Maria). doi: 10592/22365834
O’Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJN (2012) Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy. Scientific Reports. doi: 10.1038/srep00249
Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O’Connor CM, Powell DJ Jr, Mason NJ (2016) Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Molecular Therapy. Doi: 10.1038/mt.2016.146
Regan D, Guth A, Coy J, Dow S (2016) Cancer immunotherapy in veterinary medicine: Current options and new developments. The Veterinary Journal. doi: 10.1016/j.tvjl.2015.10.008
Sato BYN (2017) Eficiência da imunoterapia no tratamento do linfoma de células B em cães. Universidade Estadual Paulista Júlio de Mesquita Filho. Accessed on: May 10, 2020
Shin JH, Zhang L, Murillo-Sauca O, Kim J, Kohrt HEK, Bui JD, Sunwoo JB (2013) Modulation of natural killer cell anti-tumor activity by the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America. doi: 10.1073/pnas.1302856110
Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E (2014) Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients. Molecular Cancer Therapeutics. doi: 10.1158/1535-7163.MCT-13-0288
Smaletz O, Mutti HB (2015) Imunologia em cancerologia. In: Geller M, Scheinberg MA (eds) Diagnóstico e tratamento das doenças imunológicas. 2ed. Elsevier, Rio de Janeiro, pp 347-350.
Spezzia S (2016) O uso do bolus na radioterapia. Revista da Faculdade de Ciências Médicas de Sorocaba. doi: 10.5327/Z1984-4840201623688
Srisawat W, Nambooppha B, Pringproa K, Thongtharb A, Prachasilchai W, Sthitmatee N (2020) A preliminary study of the cross-reactivity of canine MAGE-A with hominid monoclonal antibody 6C1 in canine mammary gland tumors: an attractive target for cancer diagnostic, prognostic and immunotherapeutic development in dogs. Veterinary Sciences. doi: 10.3390/vetsci7030109
Tagawa M, Maekawa N, Konnai S, Takagi S (2016) Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma. PLoS One, doi: 10.1371/journal.pone.0150030
Tagawa M, Kurashima C, Tagaki S, Maekawa N, Konnai S, Shimbo G, Matsumoto K, Inokuma H, Kawamoto K, Miyahara K (2018) Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. PLoS One. doi: 10.1371/journal.pone.0201222
Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ III, Kraft SL, Gustafson DL, Vail DM (2010) Preclinical investigation of PEGylated tumor necrosis factor α in dogs with spontaneous tumors: phase I evaluation. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-09-2804
Wycislo KL, Fan TM (2015) The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.12603
Yazawa N, Hamaguchi Y, Poe JC, Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America. Accessed on: October 9, 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Multidisciplinary Reviews
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
